217 results about "Peptide modification" patented technology

The invention belongs to the technical field of medicine, and discloses an active targeting atherosclerotic plaque liposome and application thereof in diagnosis, a carrier material for forming the liposome comprises targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polypropylene sulfide-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), the polypropylene sulfide-polyethylene glycol (PPS-PEG) and the cholesterol (CH) are combined to form the active targeting atherosclerotic plaque liposome. The sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg, and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Gln-Cys-His- The liposome provided by the invention can improve the enrichment concentration of a fluorescent dye or a drug in local lesion, and has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on diagnosis of atherosclerosis.

The invention discloses a PEI and targeting peptide modified magnetic nano-carrier and a preparation method and application thereof. The nano-carrier is regular in morphology and uniform in particle size and has good crystallinity and magnetic performance. E5 polypeptide and RGD cyclic peptide on the surface of the nano-carrier are respectively combined with CXCR4 protein and integrin on the surface of a tumor cell, and the nano-carrier and CXCR4 are internalized into lysosome through an integrin-mediated way, so that the target protein CXCR4 is degraded. The PEI in the nano-carrier can load and deliver siRNA into tumor cells to silence the expression of CXCR4 mRNA (messenger Ribonucleic Acid). Through nucleic acid delivery and a protein targeted degradation strategy, the CXCR4 level of tumor cells is jointly reduced, the migration ability of the tumor cells is inhibited, and meanwhile, the anti-tumor effect of M1 type polarization of macrophages is activated.

The invention provides organic nanoparticles with high osteogenic performance as well as a preparation method and application thereof, and belongs to the technical field of osteogenic drug preparation. The preparation method of the organic nanoparticles with high osteogenic performance comprises the following steps: (1) preparing fluorinated polyethyleneimine, preparing double bonds from the fluorinated polyethyleneimine, and then grafting a targeting peptide E7 to obtain a carrier F-PEI-E7; and (2) entrapping an osteogenesis promoting drug in the carrier F-PEI-E7 to obtain the organic nanoparticles with high osteogenesis performance. The invention provides an innovative strategy: F-PEI is used as a carrier, an osteogenesis promoting drug (beta-GP) is entrapped, and through E7 targeting peptide (EPLQLKM) modification, precise targeting delivery of the drug is realized. The organic nanoparticles are high in stability, the in-vitro osteogenesis promoting effect is equivalent to that of a classical formula for in-vitro osteogenesis induction, and the organic nanoparticles have an excellent in-vivo osteogenesis promoting effect.

The present invention relates to the field of medical technology, and in particular to a semaglutide intermediate and a preparation method thereof, and a method for synthesizing semaglutide. The present invention screens different solvent combinations, finds a reaction system compatible with side chain tetrapeptide modification, main chain dipeptide modification and deprotection steps, and synthesizes semaglutide using a "one-pot method". The method does not require separation of any intermediate, does not involve complex operations such as isoelectric elution, separation, and redissolution of the intermediate, is simple to operate, has a high yield, and is conducive to industrial scale-up production. Further, the present invention uses a double Fmoc-protected dipeptide: Fmoc-His(Fmoc)-Aib-OH replaces Fmoc-His-Aib-OH·TFA as a starting material, which greatly reduces the use of Fmoc-His(Fmoc)-Aib-OH, and the feed amount is reduced from 8 to 10 times to 1 to 3 times, the atomic economy is increased, and the production cost is reduced.

Preparation for an siRNA and drug co-delivery system for efficiently targeting glioma initiating cells, and a use; D VAP targeting peptide modification is performed on exosomes by utilizing a click chemistry method, siRNA and mitoxantrone are loaded into the exosomes, and construction is performed to obtain a target-modified drug carrier exosome DVAP-Exo / siRNA / MIT. The target-modified exosome co-carries chemotherapeutic mitoxantrone, which has a strong killing effect on glioma initiating cells and can trigger immunogenic cell death, and a small interfering nucleic acid (siNotch 1), which is capable of reducing glioma initiating cell stemness; targeted tracking and killing of residual glioma initiating cells and tumor cells are achieved, and a new avenue is provided for glioblastoma treatment.

The present invention belongs to the field of medical technology, and discloses a liposome that actively targets atherosclerotic plaques and its application in diagnosis. The carrier material forming the liposome includes a targeting peptide R8 modified with methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polysulfide propylene-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg. The liposome of the present invention can increase the enrichment concentration of fluorescent dyes or drugs in the local lesion, has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on the diagnosis of atherosclerosis.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The invention relates to the technical field of medicines, and provides a synergetic nano chemotherapy preparation for treating pancreatic cancer and a preparation method of the synergetic nano chemotherapy preparation. According to the synergistic nano chemotherapy preparation, an RGD peptide modified lipid-mesoporous silica nano delivery system is used for simultaneously encapsulating a ferroptosis inducer Erastatin and a chemotherapy drug gemcitabine hydrochloride hcGEM. The nano synergistic treatment system not only can actively deliver the drug to the pancreatic tumor tissue with high expression of the integrin receptor in a targeted manner through the surface-modified RGD peptide, but also can realize drug synergistic treatment, and improves the killing effect of the drug on pancreatic cancer cells while reducing the toxic and side effects.

The invention relates to a mussel bionic adhesive material based on oligopeptide modified polyglutamic acid, and a preparation method and application thereof, and belongs to the field of bionic bio-based materials. The preparation method comprises the following steps: firstly, synthesizing tyrosine-containing oligopeptide through protease catalysis, and modifying the oligopeptide onto a polyglutamic acid skeleton to obtain a bionic polymer precursor; meanwhile, polyglutamic acid is modified by cysteine groups, so that a bionic high polymer material with reducibility is synthesized, and a required reducibility reaction environment is provided. The preparation method comprises the following steps: uniformly mixing the polyglutamic acid and the precursor, activating tyrosine in the precursor in a reducing environment by using tyrosinase, converting the tyrosine into dopa to finally obtain a bionic adhesive material solution, and adjusting the pH value of the solution to be close to an isoelectric point of the polyglutamic acid to realize self-assembly to form the adhesive. The adhesive prepared by the preparation method disclosed by the invention shows excellent adhesion performance and also shows good biocompatibility.

The invention provides a peptide fragment for modifying a Fe3O4 (at) Au magnetic nanoparticle and a preparation method of the Fe3O4 (at) Au magnetic nanoparticle, the peptide fragment is an alpha-peptide fragment 1 or / and a beta-peptide fragment 1, and the fragment of the peptide fragment is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, growing a layer of gold shell on the surface of Fe3O4 in situ to provide more modification sites, and then modifying PS binding peptide (PSBP) by using an Au-S bond to construct the PS NPs selective probe. The ultralow-concentration PS can be quantitatively detected only by monitoring the ultraviolet-visible absorption change of the probe. The peptide modified Fe3O4 (at) Au probe (Fe3O4 (at) Au-PSBP) has good linearity in a range of 0 to 80 pg mL <-1 >. The probe has been successfully applied to actual samples, such as bottled water, edible salt and milk. The adding standard recovery rate is 98.85%-112.10%, and the relative standard deviation (RSD) is 2.53%-13.80%. The provided Fe3O4 (at) Au-PSBP can be easily expanded to other types of NPs by simply replacing peptides, shows huge potential as a universal specific probe, and can sensitively and quickly detect low-concentration NPs in an actual sample.

A method for providing a cargo to a C-terminal end of a peptide comprises a first stage and a second stage, wherein the first stage comprises reacting the C-terminal end of the peptide with a first reactant in the presence of a first catalyst and first radiation to provide a first intermediate, wherein the first catalyst is configured to decarboxylate the C-terminal end of the peptide in the presence of the first radiation; and wherein the second stage comprises exposing the first intermediate to a second reactant.

The invention discloses RVG29 peptide modified tripterine transfersome nasal in-situ gel and a preparation method and application thereof.The in-situ gel is mainly prepared from tripterine, soybean phospholipid, cholesterol, mPEG2000-DSPE, mPEG2000-DSPE-RVG29, sodium deoxycholate and DGG, the RVG29 peptide modified tripterine transfersome nasal in-situ gel can increase the solubility of indissolvable drugs, and the RVG29 peptide modified tripterine transfersome nasal in-situ gel has the advantages that the solubility of the indissolvable drugs is improved; and the RVG29 peptide which can be specifically recognized with a dopaminergic neuron high-expression acetylcholine receptor is modified on the surface of a carrier, so that efficient active targeting endocytosis can be effectively realized, and the RVG29 peptide can be used for treating the Parkinson's disease.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention provides an engineered bacterium outer vesicle drug delivery system capable of efficiently penetrating a blood brain barrier and targeting glioblastoma as well as a preparation method and application of the engineered bacterium outer vesicle drug delivery system, and belongs to the field of drug delivery. The engineering bacteria outer vesicle drug delivery system comprises double-layer phospholipid layer vesicles BEVs, a drug delivery system and a drug delivery system, wherein the particle size of the double-layer phospholipid layer vesicles BEVs is 20 The anti-tumor drug is wrapped in the BEVs, the surface of the BEVs is modified with functional polypeptide, and the functional polypeptide is at least one of Angiopep-2 and TAT cell penetrating peptide. Animal experiments verify that the synergistic effect of the Angiopep-2 and the TAT peptide can overcome the problem of modification saturation of the Angiopep-2 peptide, and significantly improve the ability of BEVs to penetrate through BBB and target tumor tissues. Therefore, the BEVs modified by the Angiopep-2 peptide and the TAT peptide have the advantages of multi-stage targeting, high efficiency and synergy, and can effectively deliver chemotherapeutic drugs to tumor tissues.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The invention provides a combined use of a hyaluronic acid-bilirubin conjugate and honokiol in preparation of a medicine for treating osteoarthritis. The invention provides a honokiol-loaded nanoparticle, which is characterized in that a hyaluronic acid-bilirubin conjugate and honokiol are used as raw materials to prepare a nanoparticle HKL-PNPs, and then the nanoparticle HKL-PNPs is modified by a mitochondrial targeting peptide to obtain the honokiol-loaded nanoparticle HKL-MPNPs. The invention also provides a bionic nanoparticle for treating bone joints. The bionic nanoparticle is prepared by wrapping the honokiol-loaded nanoparticle with an engineered cartilage cell membrane (ECM). According to the invention, cartilage cells with high expression of IL-1R2 are obtained through a gene editing method for the first time, and mitochondrial targeted nanoparticle cores loaded with Sirtuin-3 agonists are coated by cell membranes of the cells, so that the bionic nano preparation is obtained and is used for treating OA. The prepared bionic nano preparation not only can neutralize IL-1beta mediated inflammatory reaction, but also can recover Sirtuin-3 mediated mitochondrial function imbalance, so that the result of synergistic treatment of OA is achieved.

A curcumin-containing nano-drug for treating cancer, a preparation method therefor, and use thereof. The nano-drug comprises curcumin and an extracellular vesicle expressing an anti-cancer protein TRAIL, or the nano-drug comprises curcumin and a tumor-antigen binding polypeptide-modified extracellular vesicle expressing an anti-cancer protein TRAIL. The curcumin is loaded into the extracellular vesicle for combined use, such that an extremely strong synergistic effect can be generated; the anti-cancer activity of the EV-T can be significantly enhanced by means of polypeptide modification; the composite nano-drug obtained by loading the curcumin into the extracellular vesicle can solve the problem of insolubility of curcumin, thereby further improving the anti-cancer effect.

The invention discloses a methotrexate-cationic polypeptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. According to the conjugate, MTX and cationic polypeptide with the amino acid sequence shown as SEQ ID NO: 1 are connected through chemical bonding, the membrane binding characteristic of oligomeric lysine and the transmembrane capacity of TAT cell-penetrating peptide are creatively fused, and a polypeptide carrier system with efficient cell penetrating capacity is constructed; mTX obtains amphipathy and electropositivity through peptide fragment modification, stable nanoparticles can be spontaneously formed, and the problems of poor water solubility and instable acidity of raw material medicines are effectively improved; according to the conjugate, the accumulation efficiency of the medicine at a diseased region is remarkably improved by utilizing the targeting characteristic of the polypeptide carrier, the action time of the medicine is prolonged through a precise delivery mechanism, and meanwhile, the system toxicity is reduced. The preparation method adopts mild coupling reaction conditions, and the product is high in purity and excellent in stability; the compound is suitable for treating immune-mediated inflammatory diseases and specific malignant tumors, and provides an innovative solution thought for treating related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

The invention belongs to the technical field of biological medicines, and particularly relates to a dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle as well as a preparation method and application of the dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle. The STING inhibitor is wrapped in the lipidosome to obtain the lipidosome nano-drug, and the lipidosome is used as a drug carrier, so that the water solubility and bioavailability of the lipidosome nano-drug can be improved; meanwhile, the cell-penetrating peptide and the targeted cell-penetrating peptide are used for jointly modifying the liposome nano-drug, and the cell-penetrating peptide and the targeted cell-penetrating peptide synergistically improve the cell-penetrating performance, help the drug to penetrate through an eye barrier and target retinal vascular endothelial cells, and increase the bioavailability of the drug. Moreover, the obtained nanoparticles exist in a liquid form and can be directly used as eye drops for treating eyes with retinopathy, so that a convenient and non-invasive eye disease treatment mode can better benefit patients with retinopathy, reduce retinal angiogenesis of the patients and facilitate treatment and prognosis of diseases.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

This invention relates to biodetection technology, disclosing a peptide-modified gold nanocluster, its preparation method, and its application in the detection of microplastics. The peptide-modified gold nanocluster comprises a gold nanocluster and a peptide LCI modified on the surface of the gold nanocluster, wherein the peptide LCI comprises an amino acid sequence as shown in SEQ ID NO: 1. The preparation method includes the following steps: providing functionalized modified gold nanoclusters; reacting the functionalized gold nanoclusters with the peptide LCI to attach the peptide LCI to the surface of the gold nanoclusters, forming the peptide-modified gold nanocluster. The microplastic detection method includes mixing the peptide-modified gold nanocluster with a test sample that may contain microplastics to obtain a detection solution, and performing colorimetric analysis or absorbance analysis on the detection solution. This gold nanocluster can specifically recognize polypropylene, exhibiting good specificity, low cost, and rapid detection of polypropylene microplastics.

The invention discloses a construction method and anti-tumor application of a multifunctional adoptive T cell. An active targeting peptide is fused on the surface of the multifunctional adoptive T cell through a membrane fusion liposome, and the membrane fusion liposome comprises an inner core and a shell; the inner core comprises iron oxide, a nano material and mRNA; the shell comprises phospholipid structure lipid, cationic functional lipid and active targeting peptide modified polyethylene glycol functional lipid. The multifunctional T cell provided by the invention has enhanced tumor infiltration capability, capability of overcoming immune tolerance of tumor cells and capability of reversing an immunosuppressive tumor microenvironment, and the preparation process is simple to operate, time-saving and efficient.

Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.

The invention discloses a nuclear targeting peptide modified DNA nano-particle based on a microfluidic technology and a preparation method and application thereof, and relates to the technical field of biological medicine, a poly (beta-amino ester) cationic polymer is used as a gene delivery carrier, the gene delivery carrier comprises a microtubule related sequence MTAS and a nuclear localization signal NLS oligopeptide, the gene delivery carrier and the plasmid DNA carrying the target gene are mixed to prepare nano-particles, and the plasmid DNA carrying the target gene is uniformly dispersed in the nano-particles by adopting a microfluidic mixing process; the nuclear targeting peptide modified DNA nano-particle is ingenious in structural design, the mixing uniformity of a nano-carrier and plasmid DNA is improved by adopting a micro-fluidic mixing process, the performance of the nano-particle is further improved by optimizing dialysis conditions, potential cytotoxicity and adverse effects are reduced, and the nuclear targeting peptide modified DNA nano-particle is suitable for large-scale production. And after transduction of non-activated T cells, strong tumor killing ability and cytokine secretion can be generated.

The invention discloses periodontitis targeted sustained-release gel based on epithelial training immunization and a preparation method thereof, and relates to the technical field of biological medicine, and the preparation method comprises the following steps: modifying poloxamer, and dissolving the modified poloxamer in anhydrous acetonitrile; the preparation method comprises the following steps: dissolving RGD peptide in a PBS (Phosphate Buffer Solution), adding N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and activating to obtain an activated RGD peptide solution; adding the activated RGD peptide solution into the modified poloxamer solution, and reacting at room temperature to obtain RGD peptide modified poloxamer; the RGD peptide modified poloxamer solution is mixed with a beta-glucan solution and a TLR2 agonist solution, and the periodontitis targeted slow-release gel is obtained. The gel provided by the invention specifically targets gingival epithelial cells, reduces inflammatory response and promotes periodontal tissue regeneration, has good biocompatibility and slow release performance, and can effectively control periodontitis and prevent relapse.

The invention belongs to the technical field of biological medicine, and provides a multifunctional fusion peptide modified 3D printing Ti implant constructed by a fusion peptide platform and a preparation method and application thereof. The antibacterial peptide KR-12 and the adhesion peptide GFOGER are simultaneously loaded on the surface of the 3D printing titanium implant through the specific targeting peptide minTBP-1. The sequence of the fusion peptide platform is divided into four main components: bioactive polypeptide sequences KR-12 and GFOGER; a connection unit (Linker); a lysine residue; a specific anchoring group minTBP-1; the composite material has specific loading and slow release capabilities, and utilizes synergistic antibacterial and osteogenesis functions to cope with continuous challenges of implant infection and insufficient osseointegration in biomedical equipment. Meanwhile, sterilization and bone regeneration promotion are achieved, and the method is of great importance to bone healing and enhancement of bone combination around the implant. In addition to the antibacterial effect, the synergistic effect of the antibacterial peptide KR-12 and the adhesive peptide GFOGER can significantly promote osteogenesis of the BMSCs.

The invention mainly relates to composite hydrogel of a targeted cartilage end plate as well as a preparation method and application of the composite hydrogel, and belongs to the technical field of biological medicines. The composite hydrogel of the targeting cartilage end plate comprises a cartilage targeting peptide modified drug-loaded exosome, calcium carbonate, chitosan and water, and the cartilage targeting peptide modified drug-loaded exosome comprises an exosome, a cartilage targeting peptide and salvianolic acid A. The composite hydrogel of the targeting cartilage end plate is prepared by the following steps: encapsulating salvianolic acid A by exosome derived from human mesenchymal stem cells, modifying by cartilage targeting peptide to obtain drug-loaded exosome modified by the cartilage targeting peptide, and mixing the drug-loaded exosome with calcium carbonate, chitosan and water. The compound can be used for accurately targeting cartilage endplate cells (CEPCs), remarkably relieving the inflammation of the CEPCs, changing the secretion phenotype of the CEPCs, delaying the senescence of nucleus pulposus cells (NPCs), relieving the inflammation of the NPCs and effectively treating intervertebral disc diseases.

The invention discloses a cartilage repair hydrogel material and a preparation method thereof, and relates to the technical field of biomedical materials. The preparation method comprises the following steps: adding a vitamin E water-soluble derivative D-alpha-tocopherol polyethylene glycol 1000 succinate, T-ZIF-8 modified by 2, 4-toluene diisocyanate and Mg-MOF modified by SIKVAV peptide into a mixed solution obtained by compounding silk fibroin peptide, oxidized chondroitin sulfate and 3-aminophenylboronic acid, and carrying out crosslinking under ultraviolet light, so as to obtain the cartilage repair hydrogel material. The hydrogel material prepared by the method has a three-dimensional complex cross-linked structure and is high in mechanical property and stability; through the synergistic effect of the components, an adhesion group and a hydrophilic group are created for the surface of the hydrogel material, the binding opportunity of bone cells and the surface of the hydrogel material is increased, adhesion and proliferation of the bone cells are promoted, rejection reaction of tissues to metal materials is reduced, inflammatory reaction is reduced, and collagen secretion and cartilage regeneration are promoted.

The present invention relates to peptide modified AAV capsids with increased muscle transduction efficiency. The invention also relates to derived recombinant AAV vector particles packaging a gene of interest and their use in gene therapy, in particular for the treatment of muscle diseases.